Welcome to our dedicated page for MARPAI A news (Ticker: MRAI), a resource for investors and traders seeking the latest updates and insights on MARPAI A stock.
Marpai, Inc. reports recurring developments in healthcare technology, third-party administration and pharmacy benefit management services for employers that directly fund employee health benefits. The company operates subsidiaries that provide TPA, PBM and value-oriented health plan services, including the MarpaiRx pharmacy benefit platform and the Marpai Saves initiative.
News about MRAI commonly covers MarpaiRx client wins, marketing collaborations, network access arrangements with providers such as Aetna and Cigna, financial results, operating efficiency initiatives and leadership changes tied to its health benefits administration business.
Claritev (NYSE: CTEV) announced that Marpai (OTCQX: MRAI) has expanded its relationship with Claritev beyond use of the PHCS Network for out-of-network access to include comprehensive pre- and post-payment integrity solutions across the claims lifecycle.
Marpai will adopt additional Claritev services such as Advanced Code Editing, Itemized Bill Review, DRG Validation, Data Mining, Coordination of Benefits, and Specialty Claim Reviews. According to Claritev, these capabilities are expected to help identify millions of dollars in potential savings opportunities for Marpai’s self-funded employer clients and improve claim payment accuracy. The expanded services are expected to be implemented within the next 90 days.
Marpai (OTCQX:MRAI) reported Q2 2026 revenue of $4.2 million, down 10.5% year-over-year, as customer turnover and pruning continued. Cost of revenue fell 19.0% to $3.2 million, lifting gross profit to $1.0 million and gross margin to 23.9%, a 7.9-point improvement.
Total costs and expenses declined 8.0% to $7.6 million, narrowing operating loss to $3.4 million from $3.6 million. Net loss widened slightly to $4.6 million. For the first half of 2026, revenue was $8.6 million and net loss $7.8 million. Marpai amended senior secured convertible debentures (maturity extended to April 15, 2028) and AXA notes (extended to 2029), and on July 31, 2026 priced a Series A Preferred Stock private placement for $12.1 million in gross proceeds to support operations and strategic priorities. Cash and cash equivalents were $138 thousand at June 30, 2026, excluding the new financing.
Marpai (OTCQX: MRAI) entered into securities purchase agreements with accredited investors for a $12.1 million private placement of newly designated convertible preferred stock, led by Mitchell Companies. The company sold 12,100 preferred shares at $1,000 per share, with an initial conversion price of $1.00 per common share.
According to Marpai, the proceeds are intended to accelerate growth, advance its technology-enabled TPA and PBM platform, and strengthen its financial position. The preferred stock carries an 8% dividend, payable in common shares upon a liquidity event or conversion, and will automatically convert at the applicable price following a qualified public offering or approval by 60% of preferred holders. The securities are offered under a private placement exemption and are not registered under the Securities Act of 1933.
Marpai (OTCQX:MRAI) announced debt restructuring agreements with principal lenders JGB Capital and AXA in May and July 2026, respectively. According to Marpai, the transactions are designed to reduce near-term debt service by approximately $26.4 million through 2027, ease immediate liquidity pressure, and better match obligations with projected cash flows.
The JGB Second Amendment extends the maturity of debentures issued under the JGB Purchase Agreement by one year to April 15, 2028, revises the amortization schedule, and adds certain restructuring and exit payments. The AXA Second Amendment replaces the prior repayment schedule with new minimum annual payments and extends maturity by one year to December 31, 2029, supporting ongoing operations and Marpai's business plan.
Marpai (OTCQX:MRAI) announced an estimated increase of 192,000 member lives across its TPA and MarpaiRx PBM platforms, rolling out between August 2026 and January 2027. This nearly six-fold expansion underpins management’s projection of achieving positive cash flow and positive EBITDA beginning in August 2026.
Marpai (OTCQX:MRAI) reported Q1 2026 net revenue of $4.4 million, down from $5.4 million a year earlier, with total costs and expenses reduced about 10% to $6.9 million. Operating loss was $2.5 million and net loss $3.2 million or $(0.13) per share.
The company is nearing completion of a unified cloud-based platform expected to lower IT and staffing costs from Q2 2026. Marpai highlighted a MarpaiRx marketing agreement giving potential access to about 1.5 million employee lives and a JGB debt amendment that reduces near-term cash outlays. Management targets company-wide run-rate profitability in the second half of 2026.
Marpai (OTCQX:MRAI) announced multiple new client wins across its core TPA and MarpaiRx PBM divisions, spanning diverse self-insured employer groups. These contracts are expected to expand the member base and be key drivers toward profitability and positive operating cash flow.
The agreements include comprehensive TPA, integrated pharmacy benefit management, and coordinated healthcare solutions that combine medical optimization, cost containment, and proactive member services, supporting Marpai’s data-driven, transparency-focused healthcare offering.
Marpai (OTCQX: MRAI) announced a three-year definitive marketing agreement to scale MarpaiRx PBM services via a large healthcare solutions provider affiliate network. The company called it its largest to date, aiming to expand access to self-insured employer groups and accelerate progress toward positive operating cash flow and profitability. The agreement mandates full data transparency including itemized rebate and drug-spend reporting.
Marpai (OTCQX: MRAI) executed a marketing agreement on March 9, 2026 that gives MarpaiRx potential access to a network representing up to 1.5 million covered lives. The deal creates a national distribution channel to introduce PBM, TPA, analytics, and consulting services to large employers and third-party administrators.
Marpai says its MarpaiRx platform is built to scale and expects the partnership to expand its addressable market, create a pipeline of new business opportunities, and support recurring, per-member revenue as lives are onboarded.
Marpai (OTCQX:MRAI) announced two strategic MarpaiRx client wins on Feb 23, 2026, adding >19,000 covered lives and accelerating platform expansion.
Both implementations are expected to be fully operational early in Q2 2026, expand rebate management and TPA services, and reinforce adoption by health plan consultants and brokers.